

## Bio-Images Expands in US and Japan

**Glasgow, U.K., March 6<sup>th</sup>, 2008** - Bio-Images Research Ltd. (Glasgow, U.K.) was founded in 2000 as a spin out from the Universities of Strathclyde and Glasgow. A leader and at the forefront of innovation in gamma scintigraphic imaging for early phase clinical trials, having secured numerous blue chip customers in Europe, Japan and the US with 6 steady years top line growth, Bio-Images are pleased to announce the following:

- Strategic partner in the US: Pharmaceuticals International Inc (Baltimore, Maryland)
- Strategic partner in Japan: Sansei Oka
- Acquisition of breakthrough technology: imaGIT™ licensed from Casper Associates

Not only expanding its geographic horizons, Bio-Images has launched the imaGIT™ capsule to accelerate the drug development process. Detailed knowledge of the boundaries and limitations of drug absorption through the gastro-intestinal tract is crucial for effective formulation development, and this can be successfully achieved with imaGIT™.

These three developments will not only develop the top line revenues and profitability of the company but also build upon the science credentials of a truly knowledge-based company servicing the needs and requirements of the demanding pharmaceutical industry.

These partnerships and technology breakthroughs will allow customers to be supplied with the range of services offered by Bio-Images including:

- Hospital base allowing access to patient groups and specialist medical support
- Connections with world renowned expert consultants and university links providing access to novel technologies
- Proven track record for innovative labelling techniques
- Experienced staff dedicated to quality of service
- Competitive costing

Our latest development – the imaGIT™ capsule.

Resulting from years of research by Casper Associates in the USA, the breakthrough imaGIT™ capsule technology is an ingestible, radio-controlled capsule used to evaluate regional drug absorption in humans.

Employing Bio-Images' leading non-invasive gamma scintigraphic imaging techniques, imaGIT™ is tracked through the digestive tract following oral administration and on arrival at the desired target site, release of the contained drug is triggered by an external radio signal. Blood sampling following drug release at distant sites in the intestine allows assessment of bioavailability, the results of which assist pharmaceutical companies rationalise their formulation development strategies.

**- MORE -**

Professor Howard Stevens, Chairman, commented

*“These strategic developments represent an outstanding opportunity for Bio-Images to develop its international business and also to expand the scope of the services offered to our customers. The partnership with Pharmaceuticals International Inc represents a significant expansion to our US customer base and that with Sansei Oka increases our commercial activities in the important Japanese market place. Through these partnerships we are now able to offer USA and Japanese clients access to our full range of clinical gamma scintigraphic services to assist and accelerate their formulation development programmes. The licensing of the imaGIT™ capsule represents a further expansion of our capabilities in the important area of site-specific drug absorption.”*

***Pushing knowledge boundaries, breaking through barriers,  
innovating in partnership with our customers.***

imaGIT™ capsules are supplied under licence from Casper Associates.